Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Aperta Biosciences, LLC

Clinicaltrial registered29 Oct 2026

Aperta Biosciences, LLC

29 Oct 2026: Trial registered · A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
29 Oct 2026
Title
A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis
Conditions
Blepharitis
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Guatemala
Country
Guatemala
Reference
NCT07904767
Location
Guatemala
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Aperta Biosciences, LLC

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.